# Department of Defense Pharamacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Canonical: https://abierto.us/opportunities/ht940225q9304

- Solicitation number: HT9402-25-Q-9304
- Notice type: Solicitation
- Status: Closed. Deadline was July 30, 2025 at 1:00 PM EDT
- Department: Department of Defense
- Agency: Defense Health Agency (Dha)
- Contracting office: Defense Health Agency (HT9402)
- NAICS: 325412 Pharmaceutical Preparation Manufacturing
- Product or service code: 6505 Drugs and Biologicals
- Place of performance: San Antonio, Texas
- County: Bexar County (FIPS 48029). https://abierto.us/counties/bexar-county-tx-48029
- City: San Antonio. https://abierto.us/cities/san-antonio-tx-4865000
- First posted: July 10, 2025
- Last posted: July 21, 2025
- SAM.gov: https://sam.gov/workspace/contract/opp/3e3759ac9aa44a179ebf2a4697597ee5/view

## Description

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents.

The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF).

Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

**P&T COMMITTEE MEETING:** The following August 2025 newly approved drugs will be reviewed: a. Andembry-Corticosteroids-Immune Modulators-Hereditary Angioedema Agents b. Arbli - Renin-Angiotensin Antihypertensives - Angiotensin II Receptor Blockers c. Avmapki Fakzynja Co-pack - Oncological Agents – NA d. Ensacove - Oncological Agents – NA e. Ibtrozi - Oncological Agents – NA f. Imuldosa - Targeted Immunomodulatory Biologics - IL-23 g. Khindivi - Corticosteroids-Immune Modulators – NA h. Merilog - Insulins - Rapid-Acting Agents i. nilotinib tartrate-Oncological Agents-Chronic Myelogenous Leukemia j. Tryptyr - Ophthalmic - Dry Eye k. ustekinumab-aekn - Targeted Immunomodulatory Biologics - IL-23 l. Yutrepia - Pulmonary Arterial Hypertension - Prostacyclin Nebulized m. Zelsuvmi -Antiinfectives – Miscellaneous The RFQ, including UF BPA and UF ADP appendices are attached here in.

The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9304. Pre-quotation teleconference is on July 16, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.

## Publications

- July 10, 2025: Solicitation, due July 28, 2025 at 1:00 PM EDT. Notice 027e4b1db5f449508273cdd6a758d251. https://sam.gov/workspace/contract/opp/027e4b1db5f449508273cdd6a758d251/view
- July 21, 2025: Solicitation, due July 30, 2025 at 1:00 PM EDT. Notice 3e3759ac9aa44a179ebf2a4697597ee5. https://sam.gov/workspace/contract/opp/3e3759ac9aa44a179ebf2a4697597ee5/view

## Points of contact

- Tracy Banks, tracy.e.banks2.civ@health.mil
- Stephanie Erpelding, stephanie.j.erpelding.civ@health.mil

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/ht940225q9304.